Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
Star Therapeutics announced that complete Phase 1/2 data for VGA039 demonstrated safety and clinically meaningful bleed reduction in patients with von Willebrand disease, supporting the asset's profile as Incyte awaits closing of its acquisition of Vega Therapeutics. The data, which will be presented at the ISTH 2026 Congress, supports the ongoing Phase 3 VIVID-6 study of the subcutaneous prophylactic therapy.
Key figures
- Drug Name
- VGA039
- Deal Value Usd
- 1250000000
- Phase Of Trial
- Phase 1/2
- Us patient prevalence
- 135000
- Total potential consideration
- $2.0 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.